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ABSTRACT
Introduction: Gemcitabine has been shown to exert a radiosensitizing effect in various epithelial cancers.
The aim of the present studies was to investigate whether the efficacy of radioimmunotherapy (RIT) us-
ing the 131I-labeled anti-CEA monoclonal antibody (MAb) MN-14 could be enhanced by coadministra-
tion of gemcitabine in nude mice with small (1–3 mm) peritoneal metastases of colonic origin. Materials
and methods: Firstly, the maximum tolerated dose (MTD) of gemcitabine was determined, when admin-
istered intraperitoneally at two different dosing schedules (0.11–3.0 mg/mouse/administration on days 0,
3, 6, and 9, or 0.022–0.60 mg/mouse/administration on days 0, 1, 2, 3, and 4). In two separate therapy
studies in which these two administration regimens were applied, the efficacy of gemcitabine monother-
apy was compared to that of RIT alone (125 Ci 131I-MN-14/mouse) or RIT combined with gemcitabine.
Results: When administered every 3rd day for a total of 4 administrations, or daily for 5 consecutive days,
the gemcitabine was considered safe at 0.33 mg/mouse/administration and 0.066 mg/mouse/administra-
tion, respectively. In the first therapy study, median survival of the control mice was 39 days. Gemcitabine
monotherapy at 0.11 mg or 0.33 mg/mouse/administration every 3rd day (total, 4 administrations) re-
sulted in a median survival of 52 and 57 days, respectively (p  0.0003, compared to controls). RIT alone
resulted in a median survival of 66 days (p  0.0001, compared to controls). The combination of RIT and
gemcitabine coadministration resulted in a median survival of 73 and 94 days, respectively (p  0.12, for
trend). In the second therapy study, median survival of the control mice was 48 days, which was similar
to the median survival of the mice treated with daily administrations of gemcitabine monotherapy at 0.022
mg/mouse/administration on 5 consecutive days (49 days; p  0.17). RIT alone resulted in a significantly
improved median survival of 66 days (p   0.0010, compared to controls). Combination therapy using
RIT and gemcitabine resulted in a median survival of 64 days, which did not differ significantly from the
survival of the mice treated with RIT alone (p  0.43). Conclusions: At the dose regimens employed, gem-
citabine did not enhance the efficacy of RIT of experimental small-volume peritoneal carcinomatosis of
colonic origin.
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INTRODUCTION
Despite the promising results of radioim-
munotherapy (RIT) using radiolabeled monoclo-
nal antibodies (MAbs) for the treatment of non-
Hodgkin’s lymphoma (NHL), the therapeutic
efficacy of RIT in solid tumors has been modest
at best. Solid cancers are targeted less efficiently
with radiolabeled antibodies than hematological
malignancies, which has been attributed to the
presence of various physiological barriers be-
tween the circulation and the tumor cell surface.
It has been pointed out that the vascular endo-
thelium, the relatively large transport distances in
the tissue, and the enhanced interstitial pressure
in the tumor tissue hamper the penetration of an-
tibodies into the tumor tissue to bind to their tar-
get antigen.1 As a result, tumor uptake of radio-
labeled MAbs and, consequently, the radiation
doses delivered to solid lesions are, in most cases,
too low to induce objective tumor responses. Sev-
eral innovative approaches have been pursued
with the aim to improve the efficacy of RIT.
These include strategies to improve the localiza-
tion and retention of radiolabeled MAbs in the
tumor (e.g., using high-affinity MAbs2), strate-
gies to accelerate the blood clearance of the ra-
diolabel (e.g., using antibody fragments3 or the
pretargeting method4), and strategies to increase
the sensitivity of the tumor cells to radiation (e.g.,
using radiosensitizers5–7).
Gemcitabine (2-deoxy-22-difluorocytidine-
monohydrochloride) is a pyrimidine analog and
has been shown to exert antitumor effects in a
wide range of solid tumors, as well as some
hematological malignancies.8 Gemcitabine acts
by depleting the deoxynucleoside triphosphate
pool and is incorporated in the DNA, in the same
way as 5-fluorouracil (5-FU), thereby inhibiting
DNA synthesis and, probably, DNA repair.9
Gemcitabine has been shown to sensitize a wide
range of mainly epithelial cancers to radiation,
including adenocarcinoma of the pancreas and
colon, and squamous-cell carcinoma.10 Although
in most chemoradiotherapy studies gemcitabine
was combined with external beam radiation, in
recent years, a few studies have been published
reporting radiosensitizing effects of gemcitabine
when combined with RIT in animal models of
pancreatic cancer and colon cancer.5–7,11
We have previously characterized a nude
mouse model for RIT of small-volume peritoneal
carcinomatosis of colorectal origin using the hu-
man colon carcinoma cell line, LS174T.12 RIT
using the radiolabeled anti-CEA MAb MN-14
proved very effective in inhibiting the growth of
intraperitoneally (i.p.) growing tumor nodules,
even at relatively low activity doses. 131I and
177Lu proved to be the most effective radionu-
clides in this model.13 Because gemcitabine has
previously been shown to exert some antitumor
activity against LS174T14 and improve the effi-
cacy of RIT in a subcutaneous (s.c.) tumor model
using LS174T,11 we hypothesized that gem-
citabine coadministration might sensitize the in-
traperitoneally growing LS174T xenografts to ra-
diation and improve the therapeutic efficacy of
RIT in our model of small-volume peritoneal car-
cinomatosis of colorectal origin. To test this hy-
pothesis, first the maximum tolerated dose
(MTD) of gemcitabine was determined in two
different administration regimens. Subsequently,
the effect of both administration regimens of
gemcitabine on the efficacy of RIT, using 131I-
labeled MN-14, was assessed.
MATERIALS AND METHODS
Animal Model of Small 
Peritoneal Metastases
Male nude BALB/c mice (Charles River Labo-
ratories, Sulzfeld, Germany), 8–10 weeks old and
weighing 20–25 g, were used in the experiments.
Mice were accustomed to laboratory conditions
for at least 1 week before experimental use and
were housed under nonsterile standard conditions
(temperature 20–24°C; relative humidity 50%–
60%; 12 hours light/12 hours dark) in filter-
topped cages (up to 5 mice per cage), on sawdust
with free access to animal chow (Snif Voer;
Soest, The Netherlands) and water. At the start
of therapy, all mice were housed on iron grate
floors. Peritoneal metastases were induced, as de-
scribed previously.12 In brief, mice were inocu-
lated i.p. with 1.0  106 LS174T cells (CCL 188;
American Type Culture Collection, Rockville,
MD), suspended in 500 L of RPMI-1640
medium in a 2.5-mL syringe using a 23-gauge
needle. In this model, the first macroscopic tu-
mor nodules are seen 7–10 days thereafter,
whereas bulky peritoneal carcinomatosis devel-
ops 3–5 weeks after tumor cell inoculation. All
experiments were conducted in accordance with
the principles laid out by the revised Dutch Act
on Animal Experimentation (1997) and approved
by the institutional Animal Welfare Committee
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of the Radboud University Nijmegen (Nijmegen,
The Netherlands).
Monoclonal Antibody
The murine MN-14 MAb is a high-affinity (Ka 
109 M1) class III anti-CEA IgG1 antibody, pro-
duced by a hybridoma cell-line culture, kindly
provided by Immunomedics, Inc. (Morris Plains,
New Jersey). The antibodies were purified by
protein-A chromatography, as described previ-
ously.15 Purity was checked by fast protein liq-
uid chromatography (FPLC) on a Phenomenex
(Torrance, CA) Biosep 3000 column (size 300 
7.8 mm), eluted with phosphate-buffered saline
(PBS; pH 7.2, 1 mL/min).
Radioiodination
Antibodies were radioiodinated with 131I (MDS
Nordion, Fleurus, Belgium, respectively), using
the IODOGEN method (1,3,4,6-tetrachloro-
3,6-diphenyl-glycoluril; Pierce, Rockford,
IL). Briefly, antibodies and 131I were incubated
at room temperature in 85 L of PBS (0.10 M,
pH 7.4) in a glass vial, coated with 100 g
iodogen. The reaction mixture was subsequently
separated on a PD-10 column (Amersham Bio-
sciences; Uppsala, Sweden) and eluted with PBS,
0.5% bovine serum albumin (BSA). Labeling ef-
ficiency of the radioiodination reactions was ap-
proximately 70%. Specific activities of the 131I-
MN-14 preparations were 1.6 MBq/g (43
Ci/g) and 0.64 MBq/g (17 Ci/g), respec-
tively. In a previous study, we demonstrated that
the uptake of the radiolabeled MN-14 antibody
in tumor was optimal at MN-14 protein doses up
to 25 g.12 Therefore, in this study, unlabeled
MN-14 was added to the radiolabeled antibody
preparations to adjust the total antibody protein
dose to 20 g per mouse.
Quality Control of the Radiolabeled
Antibody Preparations
The amount of free 131I was determined by in-
stant thin-layer chromatography (ITLC), using
ITLC silica gel strips (Gelman Sciences, Inc.;
Ann Arbor, MI), with 0.1 M citrate buffer, pH
6.0, as the mobile phase. Radiochemical purity
of all radiolabeled antibody preparations used in
the studies exceeded 97%. The immunoreactive
fraction (IRF) of the radiolabeled MN-14 prepa-
rations was determined on freshly trypsinized
LS174T cells, essentially as described by Lindmo
et al.16 with minor modifications. Briefly, a fixed
amount of labeled antibody (10,000 cpm) was in-
cubated with increasing concentrations of
LS174T tumor cells (1.2  106  20  106
cells/mL) in 0.5 mL binding buffer (RPMI
medium containing 0.5% BSA and 0.05% NaN3).
A duplicate of the lowest cell concentration was
incubated in the presence of an excess unlabeled
antibody to correct for nonspecific binding. Af-
ter 6 hours of incubation at 37°C, the cells were
washed and activity in the pellet was determined
in a well-type gamma counter. The inverse of the
tumor cell bound fraction was plotted against the
inverse of the cell concentration and the IRF was
calculated from the Y-axis intercept. The IRF of
the 131I-MN-14 preparations was 82% and 77%,
respectively. The radiolabeled antibody prepara-




monohydrochloride; Gemzar®) was purchased
from Ely Lilly Company (Houten, The Nether-
lands) as a powder in a glass vial (200 mg/vial).
Immediately before administration, gemcitabine
was dissolved in 0.9% sodium chloride (saline)
to the appropriate concentrations.
Studies to Determine the Maximum
Tolerated Gemcitabine Dose
To determine the MTD of gemcitabine, groups
of 6–8 mice were injected i.p. with escalating
doses of gemcitabine. Two (2) dosing regimens
were investigated in 2 separate experiments. In
the first regimen, mice were treated on days 0, 3,
6, and 9 with gemcitabine at 0.11, 0.33, 1.0, or
3.0 mg/mouse/administration. The second dosing
regimen consisted of daily intraperitoneal ad-
ministrations of 0.022, 0.066, 0.20, or 0.60
mg/mouse/administration, which was given daily
on 5 consecutive days. Control mice received
saline only. Mice were monitored daily, and body
weight was measured daily to ensure that body
weight loss did not exceed 20%.
Combination Therapy with
Radioimmunotherapy and Gemcitabine
To assess the radiosensitizing effect of gem-
citabine, 2 separate therapy experiments were
carried out in which each of the 2 gemcitabine
dosing regimens described above was combined
with RIT. In both experiments, RIT consisted of
125 Ci 131I-MN-14/mouse, which was given i.p.
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10 days after tumor cell inoculation (20
g/mouse). This activity dose represents ap-
proximately 25% of the maximum tolerated ac-
tivity dose of 131I-labeled IgG antibodies, which
has previously been shown to significantly delay
the growth of i.p. growing LS174T xenografts in
the present model.13 The majority of mice still
develop peritoneal carcinomatosis only after
9–10 weeks. Thus, we assumed that a relevant ra-
diosensitizing effect of gemcitabine could be
demonstrated at this dose level.
In the first therapy study, mice were treated
with either RIT alone (125 Ci 131I-MN-
14/mouse, 10 days after tumor cell inoculation),
gemcitabine alone (either 0.11 mg or 0.33
mg/mouse/administration on days 10, 13, 16,
and 19 after tumor cell inoculation), or 131I-
MN-14 combined with gemcitabine. In the sec-
ond therapy study, mice were treated with ei-
ther RIT alone (125 Ci 131I-MN-14/mouse, 10
days after tumor cell inoculation), gemcitabine
monotherapy (0.022 mg/per/mouse on days 10,
11, 12, 13, and 14 after tumor cell inoculation),
or RIT combined with gemcitabine. In both
studies, control mice received unlabeled MN-
14 in PBS, 0.5% BSA. Furthermore, control
mice and the mice that were treated with RIT
monotherapy received i.p. injections of saline
instead of gemcitabine (10–12 mice per group).
Mice were monitored until the humane end-
point had been reached, as determined by an
experienced and independent animal techni-
cian, who was blinded to which treatment mice
had received.17 At the time of the humane end-
point, mice were usually cachectic and drowsy,
showing signs of advanced peritoneal carcino-
matosis, such as the presence of bloody ascites
or bulky i.p. tumor growth, and were expected
to die within 1 or 2 days. When the humane
endpoint had been reached, mice were eutha-
nized by O2/CO2-asphyxiation and immedi-
ately dissected. At dissection, all macroscopic
tumor deposits were meticulously excised and
weighed. The experiments were terminated at
134 and 96 days after tumor cell inoculation,
when the remaining mice were euthanized and
dissected. The abdominal cavity was conscien-
tiously inspected. Liver, spleen, lungs, pan-
creas, greater omentum, and the diaphragm
were removed for routine histopathological
staining and immunohistochemical staining us-
ing a rabbit-anti-human anti-CEA polyclonal
antibody (A 0115; DakoCytomation, Glostrup,
Denmark).13
Statistical Analysis
Statistical analysis was performed by means of
the GraphPad Prism 4.00 software (GraphPad
Software; San Diego, CA). Single comparisons
were analyzed using the nonparametric Mann-
Whitney U test. Multiple comparisons were ana-
lyzed using the one-way analysis of variance test.
Bonferroni correction for multiple testing was ap-
plied. In the therapy studies, comparisons be-
tween the groups for differences in survival were
analyzed using the log-rank test. All tests were
two-sided; the level of statistical significance was
set at a P-value of  0.05.
RESULTS
Toxicity of Gemcitabine
To determine the dose of gemcitabine that could be
administered safely, mice received i.p. injections of
gemcitabine in 2 dosing regimens. In the first ex-
periment, in which 4 injections of gemcitabine were
given every 3rd day, 4 of 6 and 1 of 6 mice that
were treated at 3.0 and 1.0 mg/mouse/administra-
tion, respectively, died owing to severe gemc-
itabine-related toxicity during the treatment period.
Body weight loss exceeded 20% and mice suffered
from gastrointestinal toxicity, which consisted of
diarrhea, and, in some mice, hematologic toxicity,
manifesting by the presence of skin petechiae.
When administered at 0.33 or 0.11 mg/administra-
tion, none of the mice developed diarrhea or skin
petechiae. Figure 1A depicts the relative body
weight during the study. Whereas control mice
showed a gradual increase in body weight, maxi-
mum average body weight loss was 2.4%  1.4%
in the mice treated at 0.33 mg/administration (2
days after the first administration) and 1.7% 
2.2% in the mice treated at 0.11 mg/administration
(1 day after second administration; p  0.24).
In the second experiment, in which 5 daily in-
jections of gemcitabine were given, all mice treated
at 0.60 or 0.20 mg/administration and 6 of 8 mice
treated at 0.066 mg/administration died owing to
severe gemcitabine-related toxicity either during or
shortly after the treatment period. Daily adminis-
tration at 0.022 mg/administration did not result in
clinically evident toxicity. As shown in Figure 1B,
the maximum average body weight loss amounted
to 6.4%  3.6% 7 days after the first administra-
tion, which did not differ significantly from the
maximum weight loss of 4.8%  3.6% in the con-
trol mice given daily injections of saline (p  0.19).
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Based on these observations, gemcitabine was
considered safe when administered at 0.33
mg/mouse/administration every 3rd day for a to-
tal of 4 administrations, or at 0.022 mg/mouse/ad-
ministration, when administered daily for 5 con-
secutive days.
RIT Combined with Gemcitabine
Administered Every 3rd Day for 4
Consecutive Days
The survival curves for the various treatment
groups are shown in Figure 2A. Median survival
of the control mice was 39 days (range, 34–52).
Gemcitabine monotherapy at 0.11 or 0.33
mg/mouse/administration every 3rd day for a to-
tal of 4 administrations resulted in a median sur-
vival of 52 days (range, 48–62) and 57 days
(range, 52–69), respectively (p  0.0003, for
trend when compared to controls). RIT alone re-
sulted in a significantly improved median sur-
vival of 66 days (range, 55–143; p  0.0001,
compared to controls). RIT combined with 4 ad-
ministrations of gemcitabine at 0.11 or 0.33
mg/mouse/administration every 3rd day resulted
in a median survival of 73 days (range, 66–101)
510
Figure 1. (A) Relative body weight of nude mice after once-daily intraperitoneal (i.p.) administration of gemcitabine at 0, 0.11,
0.33, 1.0, or 3.0 mg/administration every 3rd day for a total of 4 administrations. (B) Relative body weight of nude mice after
once-daily i.p. administration of gemcitabine at 0, 0.022, 0.066, 0.20, or 0.60 mg/administration for a total of 5 administrations.
A
B
and 94 days (range, 66–143), respectively (p 
0.12, for trend compared to RIT alone).
The tumor weight found at dissection at the
time mice reached their humane endpoints var-
ied between 4.0  1.4 g for the mice treated with
gemcitabine monotherapy 0.11 mg/administra-
tion and 5.4  1.1 g for the mice treated with
RIT  gemcitabine 0.33 mg/administration (p 
0.24). The similar tumor mass found in the mice
in the various treatment groups demonstrates that
there was no bias in determining the humane end-
point. The method of determining and compar-
ing the survival was, therefore, reliable.
At the end of the experiment (143 days after
tumor cell inoculation), there were four long-term
survivors (2 treated with RIT alone; and 2 treated
with RIT  gemcitabine 0.33 mg/mouse/admin-
istration), without signs of i.p. tumor growth. At
dissection, 2 mice (1 from each group) had
macroscopic tumor growth (0.13 and 0.06 g, re-
spectively), whereas in the remaining 2 mice
there was no evidence of disease. Histopatholog-
ical examination of relevant organs, including the
greater omentum, mesentery, diaphragm, and
pancreas, did not reveal residual disease in any
of these mice.
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Figure 2. (A) Survival curves of mice with peritoneal LS174T tumor xenografts after intraperitoneal (i.p.) treatment with ei-
ther gemcitabine alone (either 0.11 mg or 0.33 mg/mouse/administration on days 10, 13, 16, and 19 after tumor cell inoculation),
radioimmunotherapy (RIT) alone, (131I-MN-14, 125 Ci/mouse on day 10 after tumor cell inoculation), or RIT combined with
gemcitabine. Control mice received unlabeled MN-14 (10–12 mice per group). (B) Survival curves of mice with peritoneal
LS174T tumor xenografts after i.p. treatment with either gemcitabine alone (0.022 mg/mouse/administration on days 10, 11, 12,
13, and 14 after tumor cell inoculation), RIT alone, (131I-MN-14, 125 Ci/mouse on day 10 after tumor cell inoculation), or RIT
combined with gemcitabine. Control mice received unlabeled MN-14 (10–12 mice per group).
A
B
RIT Combined with Gemcitabine
Administered Daily for 5 Consecutive Days
The survival curves for the various treatment
groups are shown in Figure 2B. Median survival
of the control mice was 48 days (range, 31–58).
Daily gemcitabine monotherapy at 0.022 mg/
mouse/administration for 5 consecutive days re-
sulted in a median survival of 49 days (range,
34–73; p  0.17, compared with controls). RIT
alone resulted in a significantly improved median
survival of 66 days (range, 45–96; p  0.0010,
compared with controls). Five (5) daily gemc-
itabine administrations at 0.022 mg/mouse/ad-
ministration starting concurrently with RIT re-
sulted in a median survival of 65 days (range,
49–91), which did not differ significantly from
the survival of the mice treated with RIT alone
(p  0.43).
The tumor weight that was found at dissection
at the time mice reached their humane endpoints
varied from 4.4  1.9 g for the mice treated with
RIT  gemcitabine and 6.0  2.0 g for the mice
treated with gemcitabine monotherapy (p 
0.15).
At the end of the experiment (96 days after tu-
mor cell inoculation), 1 mouse treated with RIT
only was still alive, without signs of i.p. tumor
growth. At dissection, this mouse had no macro-
scopic tumor growth. Histopathological exami-
nation of relevant organs, including the greater
omentum, mesentery, diaphragm, and pancreas,
did not reveal residual disease.
DISCUSSION
Radiosensitization can be defined as the use of
agents with the aim to increase the sensitivity of
tissue to radiation therapy. The primary aim of
this study was to investigate the radiosensitizing
potential of two gemcitabine treatment schedules
when combined with single-dose radioim-
munotherapy in a well-characterized animal
model of peritoneal carcinomatosis of colorectal
origin. Gemcitabine, however, failed to signifi-
cantly improve the efficacy of radioimmunother-
apy in both administration regimens tested.
Originally intended for development as an anti-
viral agent, gemcitabine was introduced in the
late 1980s as a novel and very potent pyrimidine
antimetabolite, with antitumor activity against a
wide range of epithelial cancers, including non-
small-cell- and small-cell lung cancer, breast can-
cer, pancreatic cancer, head-and-neck squamous-
cell cancer, and cervical cancer.18 Furthermore,
probably because of its interference with DNA
repair, gemcitabine has shown to be a potent ra-
diosensitizer. Although only marginally effective
when administered as a single agent in patients
with advanced colorectal carcinoma,19 gem-
citabine has been demonstrated to sensitize col-
orectal carcinoma to radiation therapy in both
preclinical and clinical studies.20,21 Interestingly,
gemcitabine can induce radiosensitization at tis-
sue concentrations 1000 times lower than typical
plasma levels obtained with the drug.21 Further-
more, the radiosensitizing effects of gemcitabine
have been shown to be dose-dependent.18 This
prompted us to conduct the experimental studies
described in this paper.
To date, four reports have been published on
the combination of experimental RIT and gem-
citabine, three of which are in animal models of
pancreatic cancer,5–7 and one in an animal model
of colon cancer.11 The group of Goldenberg pub-
lished three reports on the efficacy of combina-
tion therapy using 131I-labeled or 90Y-DOTA-la-
beled chimeric PAM4 MAb and gemcitabine in
nude mice bearing s.c. CaPan1 human pancreas
carcinoma xenografts. In their first study, mice
bearing subcutaneous tumors of approximately 1
cm3 were treated with 131I-cPAM4 (100 or 200
Ci) alone, gemcitabine alone on days 0, 3, 6, 9,
and 12 at 333 mg/m2 (2 mg/mouse), or the com-
bination of both treatments.5 Whereas both
monotherapies did not have antitumor effects, the
combination of both treatment modalities showed
a statistically significant synergistic effect, which
led the authors to conclude that gemcitabine low-
ered the threshold for antitumor response suffi-
ciently, so that the radiation dose provided by the
low-dose RIT could still carry antitumor activity.
Furthermore, combination therapy was well tol-
erated, even at the higher RIT activity dose of
200 Ci. In their second study, mice with some-
what smaller s.c. tumors (0.5 cm3) were treated
with either 3 cycles of 25 Ci 90Y-DOTA-labeled
cPAM4 only at weeks 0, 4 and 7, or once-weekly
i.p. injections of gemcitabine (6 mg/mouse,
which equals 1000 mg/m2/week), or combination
therapy.7 Both RIT and gemcitabine monother-
apy, when given as monotherapy, had some an-
titumor effects. When combined, however, there
was a supra-additive antitumor effect, at the cost
of only minimal toxicity to normal tissues, as ev-
idenced by an average loss in body weight of less
than 2% for all treatment groups. In their last re-
port, RIT using 90Y-DOTA-labeled cPAM4 was
512
combined with gemcitabine, according to the
same dose regimen as utilized in their first study,
with 131I-cPAM4 in mice bearing 1 cm3 tumors.6
Gemcitabine was not effective when given as sin-
gle treatment but still improved the efficacy of
RIT when given in combination with 90Y-DOTA-
cPAM4. Finally, Graves et al. reported on the ra-
diosensitizing effect of gemcitabine when com-
bined with pretargeted RIT in nude mice with
human colon cancer xenografts.11 In that study,
mice bearing 100–200 mm3 s.c. LS174T tumors
were treated with either pretargeted RIT, 2 i.p.
injections of gemcitabine at 50–200 mg/kg 1 day
before and 1 day after administration of 131I-la-
beled peptide, or combined modality treatment.
Whereas both pretargeted RIT and gemcitabine,
given as monotherapies, did not result in signif-
icant growth delay of the s.c. tumors, the combi-
nation of both treatment modalities resulted in a
highly significant delay of tumor growth, which
was dependent on the dose of gemcitabine used.
In our study, gemcitabine was very toxic in
both dosing regimens tested. The dose levels cho-
sen in both MTD studies were based on the doses
utilized in the above-mentioned studies, in which
gemcitabine was combined with RIT. Cardillo et
al.5 and Gold et al.7 administered gemcitabine i.p.
every 3rd day for a total of 5 administrations at
2 mg/mouse and reported a maximum mean
weight loss of only 4.5%  5.5% on day 7. In
this study, however, 1 of 6 mice treated at 1
mg/mouse died of gemcitabine-related toxicity 2
days after the first administration, whereas of the
6 mice treated at 3 mg/mouse, 4 died of acute
treatment-related toxicity. Therefore, the MTD of
gemcitabine administered every 3rd day for a 
total of 4 administrations was set at  1.0
mg/mouse. Because once-weekly administrations
of up to 6 mg/mouse have been reported as fea-
sible,6 the MTD of gemcitabine, when adminis-
tered daily for 5 consecutive days, was sought be-
tween 0.022 and 0.6 mg/mouse/administration.
Gemcitabine, however, was lethal in the major-
ity of mice treated at 0.066 mg/administration and
in all mice treated at higher doses. Hence, the
MTD of daily administrations of gemcitabine 
on 5 consecutive days was set at only 22
g/mouse/administration. The differences be-
tween the MTDs found in this study and in those
reported by other authors might be attributed to
differences in mouse strains.
The most efficacious dosing regimen of gemc-
itabine to fully exploit its radiosensitizing effect is
still a matter of investigation in both preclinical and
clinical studies. From preclinical studies on the
combination of gemcitabine and external beam ra-
diotherapy (RT), it became clear that the effects of
combination therapy become synergistic when
gemcitabine treatment precedes RT.21 In vitro stud-
ies indicated that a brief exposure (2 hours) of HT-
29 colon cancer cells to gemcitabine resulted in ra-
diosensitization for up to 48 hours.22 In RIT, the
radiation energy is delivered to the tumors over a
prolonged period of time. Furthermore, because in
a previous study we showed that the uptake of ra-
dioiodinated MN-14 in the small i.p. tumor deposits
is more than 50% ID/g for up to 72 hours postin-
jection,12 we assumed that, similar to the adminis-
tration regimen reported by the groups of Cardillo
and Gold, repeated administrations of gemcitabine
starting concurrently with RIT might effectively
sensitize the i.p. tumors to RIT. In contrast to the
synergistic effects of gemcitabine when combined
with RIT, as reported by other authors, gemcitabine
did not enhance the efficacy of RIT in our studies.
When administered every 3rd day for a total of 4
administrations, gemcitabine monotherapy still had
a modest, albeit significant, antitumor effect, which
was dose-dependent. When combined with RIT at
this dosing schedule, median survival of the com-
bination therapy groups improved relative to the
RIT monotherapy group, although the differences
did not reach statistical significance. In the second
therapy study, daily administrations of gemcitabine
at 0.022 mg/mouse/administration for 5 consecu-
tive days, which was considered the MTD of this
administration regimen, did not affect survival, nor
did it enhance the efficacy of RIT.
CONCLUSIONS
In conclusion, when given concurrently with RIT
either every 3rd day for a total of 4 administra-
tions or daily for a total of 5 consecutive days,
gemcitabine did not enhance the therapeutic ef-
ficacy of RIT at the dose regimens employed.
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